Kairos Pharma, Ltd. (KAPA) Balance Sheet
KAPA balance sheet, 2025
December 31, 2025 · U.S. dollars$6.5M assets = $199,000 liabilities + $6.3M equity
Both columns are drawn to the same scale: what KAPA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
KAPA financial health
Descriptive bands, not a rating. Fiscal 2025.
KAPA balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $14,3082020 | $6.5M2025 | +240.4%/yr | |
| Total liabilities | $357,1462020 | $199,0002025 | −11.0%/yr | |
| Shareholders’ equity | −$342,8382020 | $6.3M2025 | — | |
| Cash & short-term investments | $14,3082020 | $4.5M2025 | +215.8%/yr | |
| Total debt | $50,0002020 | $638,0002023 | +133.7%/yr | |
| Net cash (debt) | −$35,6922020 | −$545,0002023 | −$509,308 | |
| Working capital | −$342,8382020 | $5.2M2025 | +$5.5M | |
| Book value per share | −$0.212020 | $2.412025 | — | |
| Shares outstanding | 1.6M2020 | 2.6M2025 | +10.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KAPA assets
KAPA liabilities and equity
KAPA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
KAPA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $4.5M | $1.3M | $93,000 | $437,000 | $73,000 | $14,308 |
| Cash & equivalents | $4.5M | $1.3M | $93,000 | $437,000 | $73,000 | $14,308 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $896,000 | $2.9M | $8,000 | $0 | $0 | $0 |
| Total current assets | $5.4M | $4.2M | $101,000 | $437,000 | $73,000 | $14,308 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $62,000 | $222,000 | $382,000 | $542,000 | $702,000 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.1M | $1.8M | $482,000 | $57,000 | $0 | $0 |
| Total assets | $6.5M | $6.2M | $965,000 | $1.0M | $775,000 | $14,308 |
| Liabilities | ||||||
| Accounts payable | $199,000 | $992,000 | $2.4M | $1.6M | $1.5M | $307,146 |
| Short-term debt | — | — | $4,000 | $4,000 | $380,000 | $50,000 |
| Total current liabilities | $199,000 | $992,000 | $2.4M | $1.6M | $1.9M | $357,146 |
| Long-term debt | $0 | $0 | $638,000 | $582,000 | $0 | $0 |
| Other long-term liabilities | $0 | $447,999 | $0 | $0 | $0 | $0 |
| Total liabilities | $199,000 | $1.4M | $3.0M | $2.2M | $1.9M | $357,146 |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $21,000 | $14,000 | $11,000 | $10,000 | $10,000 | $192,389 |
| Retained earnings (deficit) | −$14.3M | −$8.8M | −$6.2M | −$4.4M | −$3.4M | −$1.2M |
| Total shareholders' equity | $6.3M | $4.8M | −$2.1M | −$1.2M | −$1.2M | −$342,838 |
| Key figures | ||||||
| Total debt | — | — | $638,000 | $586,000 | $380,000 | $50,000 |
| Net cash (debt) | — | — | −$545,000 | −$149,000 | −$307,000 | −$35,692 |
| Working capital | $5.2M | $3.2M | −$2.3M | −$1.2M | −$1.9M | −$342,838 |
| Tangible book value | $6.3M | $4.6M | −$2.5M | −$1.7M | −$1.9M | −$342,838 |
| Book value per share | $2.41 | $2.94 | −$1.40 | −$0.81 | −$0.64 | −$0.21 |
| Shares outstanding | 2.6M | 1.6M | 1.5M | 1.5M | 1.8M | 1.6M |
| Current ratio | 27.07 | 4.20 | 0.04 | 0.27 | 0.04 | 0.04 |
| Quick ratio | 22.57 | 1.28 | 0.04 | 0.27 | 0.04 | 0.04 |
| Equity / assets | 97.0% | 76.8% | −215.3% | −113.8% | −150.6% | −2,396.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $2.6M | $3.7M | $4.5M | $5.6M | $3.0M | $3.6M | $1.3M | $3.2M | $21,000 | $40,000 | $93,000 | $99,000 |
| Cash & equivalents | $2.6M | $3.7M | $4.5M | $5.6M | $3.0M | $3.6M | $1.3M | $3.2M | $21,000 | $40,000 | $93,000 | $99,000 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.5M | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $548,000 | $768,000 | $896,000 | $1.1M | $1.8M | $2.4M | $2.9M | $10,000 | $17,000 | $19,000 | $8,000 | $17,000 |
| Total current assets | $3.2M | $4.4M | $5.4M | $6.7M | $4.8M | $6.0M | $4.2M | $4.7M | $38,000 | $59,000 | $101,000 | $116,000 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $22,000 | $62,000 | $102,000 | $142,000 | $182,000 | $222,000 | $262,000 | $302,000 | $342,000 | $382,000 | $422,000 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.3M | $1.3M | $1.1M | $1.3M | $1.7M | $1.7M | $1.4M | $0 | $690,000 | $571,000 | $482,000 | $410,000 |
| Total assets | $4.5M | $5.7M | $6.5M | $8.1M | $6.7M | $7.9M | $5.8M | $5.0M | $1.0M | $972,000 | $965,000 | $948,000 |
| Liabilities | ||||||||||||
| Accounts payable | $265,000 | $431,000 | $199,000 | $402,000 | $676,000 | $805,000 | $992,000 | $1.5M | $2.9M | $2.7M | $2.4M | $2.2M |
| Short-term debt | — | — | — | — | — | — | — | $142,000 | $106,000 | $4,000 | $4,000 | $4,000 |
| Total current liabilities | $265,000 | $431,000 | $199,000 | $402,000 | $676,000 | $805,000 | $992,000 | $1.7M | $3.0M | $2.7M | $2.4M | $2.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $638,000 | $0 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $447,999 | $0 | $0 | $677,000 | $657,000 | $0 | $612,000 |
| Total liabilities | $265,000 | $431,000 | $199,000 | $402,000 | $676,000 | $805,000 | $992,000 | $1.7M | $3.7M | $3.4M | $3.0M | $2.8M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $21,000 | $21,000 | $21,000 | $21,000 | $18,000 | $16,000 | — | $13,000 | $11,000 | $11,000 | $11,000 | $10,000 |
| Retained earnings (deficit) | −$17.3M | −$15.9M | −$14.3M | −$12.9M | −$11.5M | −$10.1M | −$8.8M | −$7.8M | −$6.8M | −$6.5M | −$6.2M | −$5.1M |
| Accumulated other comprehensive income | — | — | — | — | — | $484,000 | — | — | — | — | — | $0 |
| Total shareholders' equity | $4.2M | $5.3M | $6.3M | $7.7M | $6.0M | $7.1M | $4.8M | $3.3M | −$2.7M | −$2.4M | −$2.1M | −$1.9M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | — | — | $142,000 | $783,000 | $661,000 | $638,000 | $616,000 |
| Net cash (debt) | — | — | — | — | — | — | — | $3.1M | −$762,000 | −$621,000 | −$545,000 | −$517,000 |
| Working capital | $2.9M | $4.0M | $5.2M | $6.3M | $4.2M | $5.2M | $3.2M | $3.1M | −$3.0M | −$2.7M | −$2.3M | −$2.1M |
| Tangible book value | $4.2M | $5.3M | $6.3M | $7.6M | $5.9M | $7.0M | $4.6M | $3.1M | −$3.0M | −$2.7M | −$2.5M | −$2.3M |
| Book value per share | $1.37 | $1.77 | $2.41 | $2.66 | $2.44 | $3.14 | $0.35 | $2.14 | −$1.45 | −$1.59 | −$1.39 | −$1.17 |
| Shares outstanding | 3.1M | 3.0M | 2.6M | 2.9M | 2.5M | 2.3M | 13.7M | 1.6M | 1.8M | 1.5M | 1.5M | 1.6M |
| Current ratio | 11.98 | 10.31 | 27.07 | 16.56 | 7.16 | 7.52 | 4.20 | 2.84 | 0.01 | 0.02 | 0.04 | 0.05 |
| Quick ratio | 9.91 | 8.53 | 22.57 | 13.87 | 4.49 | 4.49 | 1.28 | 2.83 | 0.01 | 0.01 | 0.04 | 0.04 |
| Debt / equity | — | — | — | — | — | — | — | 0.04 | — | — | — | — |
| Equity / assets | 94.1% | 92.5% | 97.0% | 95.0% | 89.9% | 89.9% | 82.8% | 66.6% | −257.7% | −247.0% | −215.3% | −197.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
KAPA financial position
At the end of fiscal 2025 (December 31, 2025), Kairos Pharma had total assets of $6.5 million (up 5.2% from a year earlier), total liabilities of $0.2 million and shareholders' equity of $6.3 million. Its current ratio was 27.07. In the latest quarter (ended June 30, 2026) total assets were $4.5 million and equity $4.2 million.
Related: KAPA income statement, KAPA cash flow statement, KAPA key metrics. See the KAPA stock overview for the latest quote and news.
KAPA balance sheet FAQ
What are Kairos Pharma's total assets?
Kairos Pharma reported total assets of $6.5 million at the end of fiscal 2025 (December 31, 2025), compared with $6.2 million a year earlier.
How much cash does Kairos Pharma have?
Kairos Pharma held $4.5 million in cash and short-term investments at the end of fiscal 2025.
What is Kairos Pharma's book value?
Kairos Pharma's shareholders' equity (book value) was $6.3 million at the end of fiscal 2025, or $2.41 per share.
What is Kairos Pharma's current ratio?
Kairos Pharma had current assets of $5.4 million and current liabilities of $0.2 million, a current ratio of 27.07 (it can cover its short-term obligations).
How much goodwill does Kairos Pharma have?
Kairos Pharma carried $0.1 million of goodwill and intangible assets, 0.9% of total assets, at the end of fiscal 2025.